Takeda Pharmaceutical Co. Ltd. · TSE:4502
Takeda Pharmaceutical — Q2 2026 Earnings Presentation
63 slides from Takeda Pharmaceutical's earnings presentation, Oct 29, 2026
Slide 1: From Transformation to Growth Acceleration
TSE: 4502 From Transformation to Growth Acceleration Horizon One: Transforming for Growth FY2026 Q2 Earnings Announcement October 29th, 2026
Slide 2: Important Notice
Important Notice For the purposes of this notice, “presentation” means this document, any oral presentation, any question and answer session Financial Information and Certain Non-IFRS Financial Measures and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limite
Slide 3: Agenda
Business Highlights Julie Kim, President & CEO Financial Highlights AGENDA Milano Furuta, Chief Financial Officer Pipeline Highlights Andy Plump, President, R&D Closing Remarks Julie Kim, President & CEO Q&A Question & Answer Session
Slide 4: Agenda
Business Highlights Julie Kim, President & CEO Financial Highlights AGENDA Milano Furuta, Chief Financial Officer Pipeline Highlights Andy Plump, President, R&D Closing Remarks Julie Kim, President & CEO Question & Answer Session
Slide 5: H1 Results on Track; Steady Progress Against FY2026 Priorities
H1 Results on Track; Steady Progress Against FY2026 Priorities FY2026 H1 Core Results Pipeline Progress Since Q1 Earnings New Product Approvals Core Revenue ORZEYFUL approved in U.S. & Japan for narcolepsy type 1 JPY 2,407.0B (USD $15.3B) -1.0% at CER MIMRYLO approved in U.S. for polycythemia vera1
Slide 6: ORZEYFUL Now Approved in the U.S., Japan & China
ORZEYFUL Now Approved in the U.S., Japan & China as the First & Only Medicine to Treat the Underlying Cause of NT1 • First-in-class oral orexin receptor 2 agonist for the treatment of narcolepsy type 1 (NT1), and the only medicine indicated to treat the disease holistically • Potential to redefine N
Slide 7: MIMRYLO Now Available in the U.S. for Polycythemia Vera
MIMRYLO Now Available in the U.S., Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera • First-in-class hepcidin mimetic approved in the U.S. for the treatment of erythrocytosis in adults with polycythemia vera • Provides rapid, stable & durable hematocrit control, the primary
Slide 8: 3 Transformative Medicines Setting Takeda on a New Growth Trajectory
3 Transformative Medicines Setting Takeda on a New Growth Trajectory ORZEYFUL MIMRYLO Zasocitinib (oveporexton) (rusfertide) Psoriasis Narcolepsy Type 1 Polycythemia Vera Orexin agonist with potential to redefine Hepcidin mimetic delivering rapid, Next-generation, highly selective oral TYK2 standard
Slide 9: A New Era Defined by Two Growth Horizons
A New Era Defined by Two Growth Horizons, Bridging from Transformation to Acceleration Horizon Two: Growth Acceleration Deliver Long-term Profitable Growth & Patient Impact Horizon One: Transforming for Growth Strengthen Competitiveness & Build Growth Engine • Drive scale and maximize revenue from f
Slide 10: Agenda
Business Highlights Julie Kim, President & CEO Financial Highlights AGENDA Milano Furuta, Chief Financial Officer Pipeline Highlights Andy Plump, President, R&D Closing Remarks Julie Kim, President & CEO Question & Answer Session
Slide 11: FY2026 H1 Results: Transformation Savings Largely Offset Investment
FY2026 H1 Results: Transformation Savings Largely Offset Significant Investment in New Launches and R&D FY 2026 H 1 (APR - SEP) FINANC IAL RESUL TS (SUM M ARY) 1 (BN YEN, except EPS) REPORTED CORE ACTUAL % ACTUAL % FY2026 H1 FY2025 H1 CHANGE FY2026 H1 FY2025 H1 CHANGE CER2 % CHANGE REVENUE 2,407.0 2
Slide 12: Transformation Program Initiatives on Track
Transformation Program Initiatives on Track Centralize & streamline corporate functions On track to deliver gross savings Reduce management layers to bring teams of ~JPY 100.0B in FY2026 closer to patients & customers ~JPY 30.0B annualized procurement savings captured in H1 Ongoing focus on procurem
Slide 13: Revenue Growth of Core In-line Brands & New Launches
Revenue Growth of Core In-line Brands & New Launches Partially Offset Headwinds in LOE and Mature Portfolio FY 2026 H 1 (APR - SEP) REVENUE VS PRIOR Y EAR (BN JPY) +8.4% 2,407.0 -1.0% at CER 210.5 2,219.5 Represent 4% of Represent 58% of total revenue; total revenue; grew +17.3% at CER grew +0.5% at
Slide 14: Transformation Program Helping to Fund Growth Investments
Transformation Program Helping to Fund Growth Investments FY 2026 H 1 (APR - SEP) C ORE OPERATING PROFIT VS PRIOR Y EAR (BN JPY) +11.2% 710.6 +0.7% at CER 66.9 639.2 Mainly launch investment for Includes ORZEYFUL, Transformation MIMRYLO, and Program savings zasocitinib FY2025 H1 Core Gross Profit OP
Slide 15: Reported Operating Profit Reflects End of VYVANSE Amortization
Reported Operating Profit Reflects end of VYVANSE Amortization Period and Lower Impairment Charges FY 2026 H 1 (APR - SEP) REPORTED OPERATING PROFIT VS PRIOR Y EAR (BN JPY) +60.4% 406.7 39.1 Includes JPY 79.8B of restructuring Mainly due to 253.6 impairment in expenses related to Transformation FY25
Slide 16: Upgrading FY2026 Full-year Outlook Mainly due to FX
Upgrading FY2026 Full-year Outlook Mainly due to FX CORE CHANGE AT CER (MANAGEMENT GUIDANCE) ORIGINAL GUIDANCE REVISED GUIDANCE REVENUE Low-single digit % decline Low-single digit % decline • Maintaining guidance for “Low-single digit %” revenue decline at Constant Exchange Rate CORE OPERATING PROFI
Slide 17: FY2026 Core Operating Profit Forecast Increased Mainly due to FX
FY2026 Core Operating Profit Forecast Increased Mainly due to FX; Maintaining Strict Cost Discipline while Investing for Growth FY 2026 REVISED C ORE OPERATING PROFIT FOREC AST (VS ORIGINAL FOREC AST) (BN JPY) 1,190.0 1,160.0 Acceleration of launch investment, mainly for zasocitinib Includes savings
Slide 18: Agenda
Business Highlights Julie Kim, President & CEO Financial Highlights AGENDA Milano Furuta, Chief Financial Officer Pipeline Highlights Andy Plump, President, R&D Closing Remarks Julie Kim, President & CEO Question & Answer Session
Slide 19: VERDICT Treat-to-Target Trial Results with ENTYVIO
VERDICT Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO Prolongs Time to First Disease-Related Complication Primary Analysis: Time to first UC-related complication1 following treatment target achievement (achieved-target population) 100 Group 3 vs. Gr
Slide 20: 3 Transformative Medicines Setting Takeda on a New Growth Trajectory
3 Transformative Medicines Setting Takeda on a New Growth Trajectory ORZEYFUL MIMRYLO Zasocitinib (oveporexton) (rusfertide) Psoriasis Narcolepsy Type 1 Polycythemia Vera Orexin agonist with potential to redefine Hepcidin mimetic delivering rapid, Next-generation, highly selective oral TYK2 standard
Slide 21: Zasocitinib Achieved Clear Skin Versus Deucravacitinib in Phase 3
A Greater Proportion of Zasocitinib-Treated Patients Achieved Clear Skin Versus Deucravacitinib in Phase 3 Head-To-Head Trial PASI 100 (Primary Endpoint) 50% • 36.5% of Zasocitinib-treated patients achieving PASI 100 response (%) achieved complete skin clearance Proportion of patients 40% 36.5% (PAS
Slide 22: Delivering Our Late-Stage Programs
Delivering Our Late-Stage Programs that are Starting to Transform Lives and Generate Significant Value FY26 FY27 FY28 - 29 Psoriasis Filed U.S., EU US Breakthrough and/or EU PRIME designations in at least one indication Psoriasis Psoriasis Psoriatic Arthritis H2H Readout2 3003 Readout3 Target Filing
Slide 23: Delivering Our Late-Stage Programs
Delivering Our Late-Stage Programs that are Starting to Transform Lives and Generate Significant Value FY26 FY27 FY28 - 29 MIMRYLO Polycythemia Vera Polycythemia Vera US Breakthrough and/or Approved US, Filed EU Target Filing JP (rusfertide) EU PRIME designations in at least one indication Japan SAK
Slide 24: Arcotatug Tavatecan Demonstrated Significant PFS & OS in Gastric Cancer
In Advanced Gastric Cancer Patients, Arcotatug Tavatecan (TAK-921) Demonstrated Clinically Meaningful and Statistically Significant PFS & OS vs. Chemotherapy 1.0 Overall Arcotatug Treatment of Survival tavatecan Physician’s Arcotatug Tavatecan met Overall survival (%) 0.8 Choice (TPC) 71.6% Median 1
Slide 25: Agenda
Business Highlights Julie Kim, President & CEO Financial Highlights AGENDA Milano Furuta, Chief Financial Officer Pipeline Highlights Andy Plump, President, R&D Closing Remarks Julie Kim, President & CEO Question & Answer Session
Slide 26: Steady Progress Against Horizon One Priorities
Steady Progress Against Horizon One Priorities Horizon One: Transforming for Growth MIMRYLO launched U.S. • Establish new growth drivers starting ORZEYFUL launched JP & CN; approved in U.S. with 3 successful launches Zasocitinib filed in U.S. and EU • Advance robust late-stage pipeline Arcotatug tav
Slide 27: Q&A
Julie Kim President & CEO Milano Furuta Chief Financial Officer Q&A Andy Plump President, R&D Rhonda Pacheco President, U.S. Business Unit Teresa Bitetti President, Oncology Business Unit Ramy Riad President, Plasma-Derived Therapies Business Unit
Slide 28: Appendix
Appendix
Slide 29: Repaid $1.5bn Bond in Q2; Debt Maturity Ladder
Repaid $1.5bn Bond in Q2 with Cash on-Hand & Plan to Repay €1.5bn Bond in Q3 without Refinancing by Long-term Debt MATURITY LADDER 1 AS OF SEPTEMBER 30, 2026 800 600 BILLION JPY RE- 400 PAID IN HYBRID DEBT 2 Q2 200 - ‖ ‖ ‖ ‖ ‖ ‖ ‖ FY 26 FY 27 FY 28 FY 29 FY 30 FY 31 FY 32 FY 33 FY 34 FY 35 FY 40 FY
Slide 30: ENTYVIO Growth Continues with Well-Established 1L Position
GASTROENTEROLOGY (GI) ENTYVIO Growth Continues with Well-Established 1L Position FY2026 H1 REVENUE FY2026 H1 Revenue JPY 541.7B (+2.7% growth at CER) Core In-line Brand GI Portfolio (BN JPY) • In the U.S., ENTYVIO remains the #1 prescribed brand in IBD (UC and Crohn’s combined)1 and is the only gut-
Slide 31: TAKHZYRO Reaching Maturity in Increasingly Competitive U.S. Market
RARE DISEASES TAKHZYRO Reaching Maturity in Increasingly Competitive U.S. Market FY2026 H1 Revenue JPY 115.6B (-7.5% change at CER) FY2026 H1 REVENUE Core In-line Brand Rare Diseases Portfolio • 8 years in the market, TAKHZYRO continues to be the #1 prescribed modern long-term prophylaxis with over
Slide 32: Balancing Near-term Growth & Margin Improvement in PDT Business
PLASMA-DERIVED THERAPIES Balancing Near-term Growth & Margin Improvement in PDT Business Immunoglobulin Albumin FY2026 H1 REVENUE FY2026 H1 Revenue JPY 423.8B FY2026 H1 Revenue JPY 69.1B PDT Portfolio (-0.3% change at CER) (-6.9% change at CER) Core In-line Brand Core In-line Brand (BN JPY) • H1 gro
Slide 33: Growth of Oncology Portfolio Driven by FRUZAQLA and ADCETRIS
ONCOLOGY Growth of Oncology Portfolio Driven by FRUZAQLA and ADCETRIS FY2026 H1 REVENUE FY2026 H1 Revenue JPY 33.4B (+12.6% growth at CER) Oncology Portfolio New Launch Brand (BN JPY) • Approved or launched in more than 40 countries +1% 320 • Key drivers include growth in newly launched markets, as
Slide 34: QDENGA Global Demand Remains Strong
VACCINES QDENGA Global Demand Remains Strong FY2026 H1 Revenue JPY 26.6B (+14.4% growth at CER) FY2026 H1 REVENUE New Launch Brand Vaccines Portfolio • 2-year contract with Brazil Ministry of Health for a total of 18 million doses (nine million in calendar year (BN JPY) 2026 and nine million in cale
Slide 35: Impact from VYVANSE U.S. Loss of Exclusivity Largely Behind Us
NEUROSCIENCE Impact from VYVANSE U.S. Loss of Exclusivity is Now Largely Behind Us FY2026 H1 REVENUE FY2026 H1 Revenue JPY 105.6B (-10.7% change at CER) Neuroscience Portfolio (BN JPY) • U.S. revenue was JPY 26.1B, declining -55.7% at CER versus prior year reflecting broad availability of generic su
Slide 36: Maximizing Potential of Marketed Portfolio Through LCM Expansions
Maximizing Potential of Marketed Portfolio Through LCM Expansions FY26 FY27 GASTROINTESTINAL ENTYVIO IV AND INFLAMMATION Filed Crohn’s/UC Peds (US, EU, JP, CN) Approved Target Filing NEUROSCIENCE TAK-7551 Ph2 Start Acute Ischemic Stroke Phase 2 study Milestone achieved ONCOLOGY mirvetuximab Target F
Slide 37: Potential Key Approvals and Phase 3 Readouts in FY2026
Potential Key Approvals and Phase 3 Readouts in FY2026 U.S. approval ORZEYFUL Narcolepsy type 1 Japan approval (oveporexton) China approval MIMRYLO Polycythemia vera U.S. approval (rusfertide) POTENTIAL KEY REGULATORY zasocitinib Psoriasis U.S. approval APPROVALS Crohn’s disease pediatric U.S. appro
Slide 38: Consolidated Development Pipeline by Phase
Consolidated Development Pipeline by Phase PHASE 1 (6 NMEs) PHASE 2 (5 NMEs + 1 LCM) PHASE 3 (8 NMEs + 4 LCMs) FILED (4 NMEs + 8 LCMs) TAK-781 | Primary Sclerosing Cholangitis zasocitinib | Crohn’s Disease zasocitinib | Pediatric Psoriasis zasocitinib | Psoriasis (US) TAK-495 | Orexin2 Receptor Agon
Slide 39: Continuing Evidence Generation and Indication Expansion
Continuing Evidence Generation and Indication Expansion PHASE 3 PHASE 3b / 4 PUBLISHED APPROVED ENTYVIO® IV ENTYVIO® IV (VERDICT) ENTYVIO® IV (VARSITY) ENTYVIO® IV Pediatric (Global)1 (Global)4,5 ENT vs. ada2 (Global) Ulcerative ENTYVIO® SC ENTYVIO® IV (EXIGEM) ENTYVIO® SC colitis Pediatric (Global)
Slide 40: Zasocitinib Studies Underway Across a Broad Range of Indications
Zasocitinib Could Redefine What is Possible with an Oral Therapy, with Studies Underway Across a Broad Range of Indications PHASE 2 START PHASE 2 READOUT PHASE 3 START PHASE 3 READOUT FILING Psoriasis March 2023 Nov 2023 Dec 2025 July 2026 Psoriasis July 2025 June 2026 H2H vs deucravacitinib Psorias
Slide 41: Glossary of Abbreviations
Glossary of Abbreviations Regional Abbreviations: CN: China; EU: Europe; JP: Japan; U.S.: United States of America 1L first line FY fiscal year PDAC pancreatic ductal adenocarcinoma 2L second line GC gastric cancer PDT plasma derived therapies 3L third line GI gastrointestinal PDUFA Prescription Dru
Slide 42: Financial Appendix
Exhibit 99.1 FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A-1 Reconciliations and Other Financial Information FY2026 H1 Reported Results with CER % Change A-4 FY2026 Q2 (Jul - Sep) Reported Results with CE
Slide 43: Definition and Explanation of Non-IFRS Measures
Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations Core Financial Measures Takeda’s Core Financial Measures, particularly Core Revenue, Core Operating Profit, Core Net Profit for the Year attributable to owners of the Company and Core EPS, exclude revenue from d
Slide 44: Free Cash Flow and Adjusted Free Cash Flow
Free Cash Flow and Adjusted Free Cash Flow Takeda defines Free Cash Flow as cash flows from operating activities less acquisition of property, plant and equipment (“PP&E”). Takeda defines Adjusted Free Cash Flow as cash flows from operating activities, subtracting payments for acquisition of PP&E, i
Slide 45: Net Debt and Adjusted Net Debt
Net Debt and Adjusted Net Debt Takeda defines Net Debt as the book value of bonds and loans on consolidated statements of financial position adjusted only for cash and cash equivalents and Adjusted Net Debt first by calculating the sum of the current and non-current portions of bonds and loans as sh
Slide 46: FY2026 H1 Reported Results with CER % Change
FY2026 H1 Reported Results with CER % Change (Million USD, AER CER except EPS) FY2025 FY2026 (Billion JPY, except EPS) FY2026 H1 H1 H1 JPY Change % Change % Change Convenience USD Translation Revenue 2,219.5 2,407.0 187.5 8.4 % (1.0) % 15,307 Cost of sales (764.7) (798.8) (34.0) (4.5) % 4.6 % (5,080
Slide 47: FY2026 Q2 Reported Results with CER % Change
FY2026 Q2 (Jul - Sep) Reported Results with CER % Change (Million USD, AER CER except EPS) FY2025 Q2 FY2026 Q2 (Billion JPY, except EPS) FY2026 Q2 (Jul-Sep) (Jul-Sep) (Jul-Sep) JPY Change % Change % Change Convenience USD Translation Revenue 1,112.8 1,187.1 74.3 6.7 % (1.6) % 7,549 Cost of sales (38
Slide 48: FY2026 H1 Core Results with CER % Change
FY2026 H1 Core Results with CER % Change (Million USD, AER CER except EPS) FY2025 FY2026 (Billion JPY, except EPS) FY2026 H1 H1 H1 JPY Change % Change % Change Convenience USD Translation Revenue 2,219.5 2,407.0 187.5 8.4 % (1.0) % 15,307 Cost of sales (765.2) (799.4) (34.3) (4.5) % 4.6 % (5,084) Gr
Slide 49: FY2026 Q2 Core Results with CER % Change
FY2026 Q2 (Jul-Sep) Core Results with CER % Change (Million USD, AER CER except EPS) FY2025 Q2 FY2026 Q2 (Billion JPY, except EPS) FY2026 Q2 (Jul-Sep) (Jul-Sep) (Jul-Sep) JPY Change % Change % Change Convenience USD Translation Revenue 1,112.8 1,187.1 74.3 6.7 % (1.6) % 7,549 Cost of sales (380.2) (
Slide 50: FY2026 H1 Reconciliation from Reported to Core
FY2026 H1 Reconciliation from Reported to Core Reported to Core adjustments (Billion JPY, except EPS and number of shares) Reported Amortization of Impairment of Other Core intangible intangible operating income/ Others assets assets expenses Revenue 2,407.0 2,407.0 Cost of sales (798.8) (0.7) (799.
Slide 51: FY2026 Q2 Reconciliation from Reported to Core
FY2026 Q2 (Jul-Sep) Reconciliation from Reported to Core Reported to Core adjustments (Billion JPY, except EPS and number of shares) Reported Amortization of Impairment of Other Core intangible intangible operating income/ Others assets assets expenses Revenue 1,187.1 1,187.1 Cost of sales (392.1) (
Slide 52: FY2025 H1 Reconciliation from Reported to Core
FY2025 H1 Reconciliation from Reported to Core Reported to Core adjustments (Billion JPY, except EPS and number of shares) Reported Amortization of Impairment of Other Core intangible intangible operating income/ Others assets assets expenses Revenue 2,219.5 2,219.5 Cost of sales (764.7) (0.4) (765.
Slide 53: FY2025 Q2 Reconciliation from Reported to Core
FY2025 Q2 (Jul-Sep) Reconciliation from Reported to Core Reported to Core adjustments (Billion JPY, except EPS and number of shares) Reported Amortization of Impairment of Other Core intangible intangible operating income/ Others assets assets expenses Revenue 1,112.8 1,112.8 Cost of sales (380.1) (
Slide 54: FY2026 H1 Adjusted Free Cash Flow
FY2026 H1 Adjusted Free Cash Flow (Million USD) FY2025 FY2026 FY2026 H1 (Billion JPY) JPY Change % Change H1 H1 Convenience USD Translation Net profit 112.5 305.7 193.2 171.6 % 1,944 Depreciation and amortization, and impairment losses 453.8 358.3 (95.4) 2,279 Decrease (increase) in trade working ca
Slide 55: FY2026 H1 Adjusted Net Debt to Adjusted EBITDA
FY2026 H1 Adjusted Net Debt to Adjusted EBITDA ADJUSTED NET DEBT/ADJUSTED EBITDA RATIO NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS FY2026 FY2025 FY2026 JPY (Billion JPY) (Billion JPY) H1 H1 H1 Change % Change Book value of bonds and loans on consolidated statement of Net cash from operating
Slide 56: FY2025 Adjusted Net Debt to Adjusted EBITDA
FY2025 Adjusted Net Debt to Adjusted EBITDA ADJUSTED NET DEBT/ADJUSTED EBITDA RATIO NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS JPY (Billion JPY) FY2025 (Billion JPY) FY2024 FY2025 Change % Change Book value of bonds and loans on consolidated statement of Net cash from operating activities
Slide 57: FY2026 H1 Net Profit to Adjusted EBITDA Bridge
FY2026 H1 Net Profit to Adjusted EBITDA Bridge FY2025 FY2026 (Billion JPY) JPY Change % Change H1 H1 Net profit 112.5 305.7 193.2 171.6 % Income tax expenses (benefit) 66.3 13.0 Depreciation and amortization 366.6 327.5 Interest expense, net 63.3 73.0 EBITDA 608.7 719.1 110.4 18.1 % Impairment losse
Slide 58: FY2026 H1 Net Profit to Adjusted EBITDA LTM Bridge
FY2026 H1 Net Profit to Adjusted EBITDA LTM Bridge FY2025 FY2025 FY2026 FY2026 (Billion JPY) Full Year H1 H1 H1 LTM*1 (Apr - Mar) (Apr - Sep) (Apr - Sep) (Oct - Sep) Net profit (152.1) 112.5 305.7 41.0 Income tax expenses (benefit) 9.8 66.3 13.0 (43.5) Depreciation and amortization 721.1 366.6 327.5
Slide 59: FY2026 H1 CAPEX, Depreciation and Amortization and Impairment Losses
FY2026 H1 CAPEX, Depreciation and Amortization and Impairment Losses FY2025 FY2026 Revised Forecast (Billion JPY) JPY Change % Change H1 H1 (October 29, 2026) Capital expenditures*1 127.9 159.0 31.1 24.3 % 330.0 - 380.0 Tangible assets 88.0 98.5 10.5 11.9 % Intangible assets 39.9 60.5 20.6 51.6 % De
Slide 60: FY2026 Full Year Detailed Forecast
FY2026 Full Year Detailed Forecast Original Forecast Revised Forecast JPY % (BN JPY) (October 29, 2026) Change Change Variances (May 13, 2026) FX benefits and higher-than-expected revenue from LOE and Mature Portfolio partially offset by Revenue 4,640.0 4,700.0 60.0 1.3% the underperformance of Albu
Slide 61: FY2026 Full Year Reconciliation to Core Operating Profit Forecast
FY2026 Full Year Reconciliation from Reported Operating Profit to Core Operating Profit Forecast Reported to Core adjustments (Billion JPY) Reported Amortization of Impairment of Core Other operating intangible intangible income (expenses) assets assets Revenue 4,700.0 4,700.0 Cost of sales (1,617.0
Slide 62: FY2026 Full Year FX Rates Assumptions and Currency Sensitivity
FY2026 Full Year FX Rates Assumptions and Currency Sensitivity vs. Forecast Average Exchange Rates vs. JPY Impact of depreciation of yen from October 2026 to March 2027 (100 million JPY) Core FY2025 H1 FY2026 H1 FY2026 Full Year FY2026 H2 Operating Revenue Net Profit Operating Actual Actual Assumpti
Slide 63: Takeda Investor Relations
Takeda Investor Relations: [email protected] TSE: 4502
Takeda Pharmaceutical Company — Q2 2026 Earnings Presentation on 6ix